Aqilion expands its pipeline
AQILION AB (publ) announces an expansion of its pipeline through the nomination of PKCtheta as the target of a new immunology project.Aqilion’s aims at the discovery and development of differentiated and effective treatments for autoimmune and inflammatory diseases. The PKCtheta kinase plays a critical role in T-cell receptor signaling and is believed to be centrally involved in the pathogenesis of T-cell mediated inflammatory and autoimmune diseases e.g. ulcerative colitis and rheumatoid arthritis. PKCtheta has garnered significant attention from the pharmaceutical industry and, using our
